CRISPR

Homozygous familial hypercholesterolemia (HoFH) is a rare form of familial hypercholesterolemia, an autosomal-dominant genetic disorder of lipid metabolism characterized by strikingly elevated levels of low-density lipoprotein cholesterol (LDL-C).  Heterozygous Familial Hypercholesterolemia vs. Homozygous F...

CRISPR technology or CRISPR/Cas9 technology is a genome-editing tool derived from the bacterial defense system against viruses and plasmids. The system comprises the Cas9 nuclease enzyme to create site-directed dsDNA (double-stranded DNA) break and a guide RNA, which is a predesigned 20 bp long RNA sequence within ...

FDA Gives Green Signal to First Measles Vaccine in Almost 50 Years GSK announced that the company's vaccine for protection against mumps, measles, and rubella (MMR) had been approved by the U.S. FDA. According to data from six clinical studies, the company filed a Biologics License Application in August 2021. ...

Artificial Intelligence (AI), with its wide range of applications, is enhancing the speed and accuracy of businesses across various industries such as manufacturing, healthcare, finance, marketing, and several others. To take advantage, globally, companies, whether big or small, are actively adopting artificial int...

AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a famil...

GSK to spend USD 100 M to boost its vaccine production Drug maker GlaxoSmithKline has announced to invest USD100 million in its vaccine production site in Montana-one of its nine manufacturing units in the USA. In order to cope with the supply issues GSK faced last year, the company wishes to boost its vaccine p...

Inozyme Pharma Raises USD 67 Million in Series A2 Financing Inozyme Pharma- a Boston-based biotechnology company, solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The company plans to use this funding to progress its lead asset INZ-701, into clinical trials. INZ-701...

Stem Cells therapies and CRISPR gene-editing are not new. Having able to grow the desired cells and manipulate the genome system have proved to be the most important breakthrough so far. We all are aware of the fact that Embryos possess the potential to produce pluripotent cells that researchers experiment on t...

The ability of CRISPR to change an organism’s DNA has lead researchers, particularly from Nigeria to use the tool to perform diagnostic tests. Since CRISPR therapeutics is all about targeting the genome-specific sequence, the test is believed to pinpoint the exact viral strain circulating. The recent epidemi...

Axovant tips nelotanserin from small molecule R&D Axovant has stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The dull data compelled Axovant to miss the drug and finish its pivot from small molecules to gene therapies. The parent comp...